NCT07439653PHASE1, PHASE2Recruiting
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
TORL Biotherapeutics, LLC
Start Date
3/31/2026
Completion Date
9/30/2029
Summary
A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
Eligibility Criteria
Age Range: 18 years to No maximum
Inclusion Criteria:
* Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT.
* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
* At least 1 measurable lesion per Lugano criteria.
* Tumor tissue is available.
* Adequate organ function
Exclusion Criteria:
* T-cell lymphoma
* CLL or SL
* Burkitt lymphoma and high-grade B-cell lymphoma
* CNS involvement
* Peripheral neuropathy \> Grade 2
* Uncontrolled medical conditions
* Viral infections
Interventions
DRUG
TORL-5-700
DRUG
TORL-5-700 at MTD/RP2D
DRUG
TORL-5-700 at MTD/RP2D in combination with another agent
Conditions
Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Locations
Providence Medical Foundation
Fullerton, California 92835
United States
Cancer and Blood Specialty Clinic, Los Alamitos
Los Alamitos, California 90720
United States
UCLA
Santa Monica, California 90404
United States
Stanford University
Stanford, California 94305
United States
University of California Miami, Sylvester Comprehensive Cancer Center
Miami, Florida 33136
United States
University of Iowa Health Care
Iowa City, Iowa 52242
United States
Cancer Center of Kansas, Wichita
Wichita, Kansas 67214
United States
Sarah Cannon Research Institute
Nashville, Tennessee 37203
United States
University of Texas Southwestern Medical Center
Dallas, Texas 75390
United States